Board allots 1,82,400 equity shares as 60,800 warrants convert after 1:2 bonus issue

Board meeting outcome: 1,82,400 equity shares allotted to non-promoter allottees as 60,800 warrants are converted.

Sat 3 Oct 2026

Equity shares allotted

1,82,400 equity shares allotted to non-promoter allottees

Warrants converted

60,800 warrants are converted

Warrant issue price

Rs. 1,250/- per warrant

Upfront amount paid

Rs. 312.50/- (25%) was paid upfront, balance now received

Warrants outstanding

2,667 warrants remain outstanding for conversion

Board outcome: warrants converted into equity shares

Fredun Pharmaceuticals' board, at its meeting on October 03, 2026, allotted 1,82,400 equity shares of face value Rs. 10/- each. The shares went to warrant holders who had paid the balance consideration and applied to convert 60,800 warrants. The issuance is a preferential issue under Chapter V of the SEBI ICDR Regulations, 2018.

Warrant terms

• The warrants were allotted on December 29, 2025 at an issue price of Rs. 1,250/- per warrant.
• Of this, Rs. 312.50/- per warrant, being 25% of the issue price, was payable upfront. The update states the total consideration on the 60,800 convertible warrants is received.
• After the 1:2 bonus issue, the entitlement attached to the outstanding warrants was proportionately adjusted, giving each outstanding warrant the right to three equity shares, with the exercise price revised accordingly.

Allottees

• All 10 allottees are non-promoter investors; the update names them, along with their warrants and shares, in a table.
• As printed in that table's totals: 72,000 warrants allotted on December 29, 2025, 60,800 equity shares allotted upon conversion on October 03, 2026, 2,667 warrants outstanding for conversion, and 1,82,400 after the effect of the 1:2 bonus issue.

Share details

• The equity shares will be allotted in dematerialised form.
• They will rank pari passu with the existing equity shares of the company in all respects.
• Against cancellation or termination of the proposal for issuance of securities, the update states "Not Applicable".

How to read it

• Converting warrants into shares increases the number of equity shares in issue, and the company says the consideration on these warrants has been received.
• The conversion follows the warrant allotment made in December 2025 and the 1:2 bonus issue, which raised the number of shares each warrant could be exchanged for.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.